Tanzeum (GlaxoSmithKline LLC)


Welcome to the PulseAid listing for the Tanzeum drug offered from GlaxoSmithKline LLC. This GLP-1 Receptor Agonist [EPC],Glucagon-like Peptide-1 (GLP-1) Agonists [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: GlaxoSmithKline LLC
NON-PROPRIETARY NAME: albiglutide
SUBSTANCE NAME: ALBIGLUTIDE
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: GLP-1 Receptor Agonist [EPC],Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]
ROUTE: SUBCUTANEOUS
DOSAGE FORM: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
MARKETING CATEGORY NAME: BLA
START MARKETING DATE: 2014-04-15
END MARKETING DATE: 0000-00-00


Tanzeum HUMAN PRESCRIPTION DRUG Details:

Item DescriptionTanzeum from GlaxoSmithKline LLC
LABELER NAME: GlaxoSmithKline LLC
DEA SCHEDULE:
ACTIVE STRENGTH: 30(mg/.5mL)
START MARKETING DATE: 2014-04-15
END MARKETING DATE: 0000-00-00
PRODUCT ID: 0173-0866_330e923a-4667-456a-b240-d06efd7f7378
PRODUCT NDC: 0173-0866
APPLICATION NUMBER: BLA125431

Other ALBIGLUTIDE Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
GlaxoSmithKline LLCTanzeum